Alpha 2.0
Login Register
» Articles » PMID: 38882462

Letermovir Primary Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: Real-Life Data from a University Hospital in Argentina

Overview
Journal Mediterr J Hematol Infect Dis
Specialty Infectious Diseases
Date 2024 Jun 17
PMID 38882462
Authors
Fabian Herrera
Diego Torres
Marcia Querci
Andres Nicolas Rearte
Elena Temporiti
Leandro Riera
Patricio Duarte
Cristina Videla
Pablo Bonvehi
Affiliations
Soon will be listed here.
Abstract

Background: Cytomegalovirus (CMV) infection remains the most common clinically significant infection after allogeneic hematopoietic stem cell transplantation (allo-HCT) and is associated with considerable morbidity and mortality.

Objectives: The present study was designed to describe and compare the incidence of untreated CMV reactivation (uCMVr), clinically significant infection (cs-CMVi) and disease (CMVd), as well as CMV-related hospitalization and outcome of allo-HCT patients, either treated with letermovir (LET) primary prophylaxis or managed with preemptive therapy (PET).

Methods: This is a prospective observational cohort study of adult CMV seropositive allo-HCT patients who either received primary prophylaxis with LET within the first 100 days after HCT or were managed with PET.

Results: The study population comprised 105 patients (28 in the LET group and 77 in the PET group). Compared to the PET group, patients in the LET group received more allo-HCT from alternative donors (54.5% vs. 82.14%, ). More than half of the patients in both groups were classified as high risk for CMVd. In the LET vs. PET group, cs-CMVi and CMVd developed respectively in 0 vs. 50 (64.94%), , and 0 vs. 6 (7.79%), . In the LET group, uCMVr occurred in 5 (17.8%) and were all considered blips. Hospital admissions related to cs-CMVi or CMVd in the PET group vs. LET group were 47 (61.04%) vs. 0, respectively, . No differences were observed in 100-day mortality.

Conclusions: LET primary prophylaxis proved effective in preventing cs-CMVi and CMVd and reducing hospitalizations in allo-HCT adults. Blips can occur during prophylaxis and do not require LET discontinuation.

References
1.
Girmenia C, Barosi G, Piciocchi A, Arcese W, Aversa F, Bacigalupo A . Primary prophylaxis of invasive fungal diseases in allogeneic stem cell transplantation: revised recommendations from a consensus process by Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biol Blood Marrow Transplant. 2014; 20(8):1080-8. DOI: 10.1016/j.bbmt.2014.02.018. View
2.
Teira P, Battiwalla M, Ramanathan M, Barrett A, Ahn K, Chen M . Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016; 127(20):2427-38. PMC: 4874224. DOI: 10.1182/blood-2015-11-679639. View
3.
Johnsrud J, Nguyen I, Domingo W, Narasimhan B, Efron B, Brown J . Letermovir Prophylaxis Decreases Burden of Cytomegalovirus (CMV) in Patients at High Risk for CMV Disease Following Hematopoietic Cell Transplant. Biol Blood Marrow Transplant. 2020; 26(10):1963-1970. DOI: 10.1016/j.bbmt.2020.07.002. View
4.
Patterson T, Thompson 3rd G, Denning D, Fishman J, Hadley S, Herbrecht R . Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016; 63(4):433-42. PMC: 4967611. DOI: 10.1093/cid/ciw444. View
5.
Goldsmith S, Abid M, Auletta J, Bashey A, Beitinjaneh A, Castillo P . Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. Blood. 2021; 137(23):3291-3305. PMC: 8351903. DOI: 10.1182/blood.2020009362. View